TVTX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

142.18M

+90.12%

0.220

-146.81%

133.51M

+63.35%

0.072

-137.72%

153.11M

+33.78%

0.262

+101.28%

Estimates Revision

The market is revising Upward the revenue expectations for Travere Therapeutics, Inc. (TVTX) for FY2025, with the revenue forecasts being adjusted by 20.08% over the past three months. During the same period, the stock price has changed by 32.64%.

Revenue Estimates for FY2025

Revise Upward

+20.08%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+32.64%

In Past 3 Month

14 Analyst Rating

Wall Street analysts forecast TVTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TVTX is 40.09 USD with a low forecast of 31.00 USD and a high forecast of 49.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

12 Buy

2 Hold

0 Sell

Strong Buy

Current: 0.000

Low

31.00

Averages

40.09

High

49.00

Current: 0.000

Low

31.00

Averages

40.09

High

49.00

Cantor Fitzgerald

Overweight

maintain

2025-12-24

Reason

Cantor Fitzgerald

Price Target

2025-12-24

maintain

Overweight

Reason

Cantor Fitzgerald notes that Travere Therapeutics is up 15% following the announcement from Dimerix that the FDA, in written feedback, reconfirmed the percentage reduction of proteinuria at 2 years as an appropriate endpoint for full approval in FSGS for their drug, DMX-200. Given how close the Filspari FSGS PDUFA is, FDA's consistent messaging on proteinuria reduction as an approvable endpoint for FSGS is a positive for Travere Therapeutics, the firm says. Also, it seems that the FDA could be exercising some flexibility on the specific proteinuria based endpoint that will be sufficient for full approval, Cantor adds. Overall, the firm sees the news as a very positive update for Overweight-rated Travere as FDA's messaging on proteinuria as an approvable FSGS endpoint is consistent for now, and Dimerix likely has some wood to chop on getting accelerated approval.

Piper Sandler

Allison Bratzel

Neutral

maintain

$26 -> $35

2025-11-04

Reason

Piper Sandler

Allison Bratzel

Price Target

$26 -> $35

2025-11-04

maintain

Neutral

Reason

Piper Sandler analyst Allison Bratzel raised the firm's price target on Travere Therapeutics to $35 from $26 and keeps a Neutral rating on the shares. The firm notes Filspari had a strong Q3, with U.S. revenue of $90.9M coming in about $12M above consensus, representing +26% quarter-over-quarter growth and an impressive 155% year-over-year growth. Piper sees the upcoming regulatory decision for FSGS as the primary near-term driver for shares, with regulatory uncertainty leading the firm to remain on the sidelines.

TD Cowen

Tyler Van Buren

Buy

maintain

$30 -> $40

2025-10-31

Reason

TD Cowen

Tyler Van Buren

Price Target

$30 -> $40

2025-10-31

maintain

Buy

Reason

TD Cowen analyst Tyler Van Buren raised the firm's price target on Travere Therapeutics to $40 from $30 and keeps a Buy rating on the shares. The firm said Q3 Filspari sales of $91MM (+26% Q/Q) led to an impressive 15% beat over consensus, underscoring strong demand, PSF pull-through, and persistence.

Citi

Yigal Nochomovitz

Buy

maintain

$34 -> $48

2025-10-31

Reason

Citi

Yigal Nochomovitz

Price Target

$34 -> $48

2025-10-31

maintain

Buy

Reason

Citi analyst Yigal Nochomovitz raised the firm's price target on Travere Therapeutics to $48 from $34 and keeps a Buy rating on the shares. Citi also added an "upside 90-day catalyst watch" on Travere. The firm expects FDA approval by the action date of January 13, 2026, for Filspari for the treatment of focal segmental glomerulosclerosis. Citi believes "everything seems to be moving in a positive direction" for Travere following the Q3 report.

Evercore ISI

Outperform

NULL

downgrade

$45 -> $35

2025-10-01

Reason

Evercore ISI

Price Target

$45 -> $35

2025-10-01

downgrade

Outperform

NULL

Reason

Evercore ISI lowered the firm's price target on Travere Therapeutics to $35 from $45 and keeps an Outperform rating on the shares. All eyes are on the FSGS PDUFA on January 13, 2026, given that this has \"implications for the whole renal field,\" according to the analyst, who sees this as an up 30%-35% or down 60%-65% event for Travere.

Stifel

Hold

maintain

$20 -> $25

2025-09-12

Reason

Stifel

Price Target

$20 -> $25

2025-09-12

maintain

Hold

Reason

Stifel raised the firm's price target on Travere Therapeutics to $25 from $20 and keeps a Hold rating on the shares following the announcement that FDA no longer plans to hold an advisory committee meeting for the sparsentan sNDA in focal segmental glomerulosclerosis. While the firm finds this \"unexpected,\" it notes that more recent precedent from FDA AdCom cancelations have been taken as positive indicators and is updating its model to reflect 90% odds of success of approval.

Valuation Metrics

The current forward P/E ratio for Travere Therapeutics Inc (TVTX.O) is 39.39, compared to its 5-year average forward P/E of 38.50. For a more detailed relative valuation and DCF analysis to assess Travere Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

38.50

Current PE

39.39

Overvalued PE

340.65

Undervalued PE

-263.65

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

12.35

Current EV/EBITDA

18.37

Overvalued EV/EBITDA

86.82

Undervalued EV/EBITDA

-62.12

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

5.31

Current PS

5.90

Overvalued PS

7.28

Undervalued PS

3.34

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

TVTX News & Events

Events Timeline

No data

News

4.5

01-06NASDAQ.COM

XBI Price Fluctuation Analysis: 52-Week High at $126.50

1.0

01-05Businesswire

Travere Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026

8.0

01-05NASDAQ.COM

Reddit Inc (RDDT) Options Trading Volume Hits 28,033 Contracts, Over 70% of Daily Average

People Also Watch

Frequently Asked Questions

What is Travere Therapeutics Inc (TVTX) stock price today?

The current price of TVTX is 34.58 USD — it has decreased -2.87 % in the last trading day.

What is Travere Therapeutics Inc (TVTX)'s business?

Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.

What is the price predicton of TVTX Stock?

What is Travere Therapeutics Inc (TVTX)'s revenue for the last quarter?

Travere Therapeutics Inc revenue for the last quarter amounts to 164.86M USD, increased 162.11 % YoY.

What is Travere Therapeutics Inc (TVTX)'s earnings per share (EPS) for the last quarter?

Travere Therapeutics Inc. EPS for the last quarter amounts to 0.25 USD, decreased -135.71 % YoY.

What changes have occurred in the market's expectations for Travere Therapeutics Inc (TVTX)'s fundamentals?

How many employees does Travere Therapeutics Inc (TVTX). have?

Travere Therapeutics Inc (TVTX) has 385 emplpoyees as of January 10 2026.

What is Travere Therapeutics Inc (TVTX) market cap?

Today TVTX has the market capitalization of 3.09B USD.